This meta-analysis showed that 18F-PSMA-1007 PET/CT has a higher diagnostic efficacy for prostate cancer both in the setting of primary prostate cancer and biochemical recurrence, as compared to other PSMA ligands. The gene discussed is FOLH1; the disease is prostate carcinoma.